Xenetic Biosciences Inc
$ 3.38
2.11%
02 Jun - close price
- Market Cap 7,583,400 USD
- Current Price $ 3.38
- High / Low $ 3.45 / 3.28
- Stock P/E N/A
- Book Value 3.23
- EPS -1.19
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.37 %
- 52 Week High 13.93
- 52 Week Low 1.90
About
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
Analyst Target Price
$40.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-12 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-19 | 2024-11-12 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-10 | 2023-08-11 |
| Reported EPS | -0.1992 | -0.22 | -0.33 | -0.45 | -0.59 | -0.68 | -0.28 | -0.83 | -0.78 | -0.77 | -0.69 | -0.69 |
| Estimated EPS | None | -0.52 | -0.84 | -0.79 | -0.72 | -0.2 | -0.14 | -0.83 | -0.79 | -0.87 | -1.12 | -1.13 |
| Surprise | 0 | 0.3 | 0.51 | 0.34 | 0.13 | -0.48 | -0.14 | 0 | 0.01 | 0.1 | 0.43 | 0.44 |
| Surprise Percentage | None% | 57.6923% | 60.7143% | 43.038% | 18.0556% | -240% | -100% | 0% | 1.2658% | 11.4943% | 38.3929% | 38.9381% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XBIO
2026-06-01 13:09:33
Xenetic Biosciences Inc. presented preclinical data showing that DNase I enhances CAR-T cell expansion and antitumor efficacy in hematologic cancer models. The studies demonstrated that DNase I degrades extracellular DNA, preserves CAR-T cell function, and improves tumor control, suggesting it could be an effective adjunctive therapy. The company, which holds more cash than debt, is focused on advancing its systemic DNase program into clinical trials for solid tumors.
2026-06-01 13:09:32
Xenetic Biosciences announced positive preclinical data presented at the ASCO 2026 Annual Meeting, demonstrating that DNase I significantly improves CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. The findings suggest that DNase I degrades immunosuppressive extracellular DNA and neutrophil extracellular traps (NETs), which are key drivers of CAR-T cell exhaustion, thereby enhancing tumor control and survival. This data supports the continued clinical development of DNase I as an adjunctive therapy to augment CAR-T cell therapies in difficult-to-treat cancers.
2026-06-01 13:09:32
Xenetic Biosciences (NASDAQ: XBIO) presented preclinical and translational data at ASCO 2026 showing that its DNase I significantly improved CAR-T cell expansion, persistence, and tumor control in aggressive B cell malignancy models. The data also include observations from a pediatric Burkitt lymphoma patient where DNase I co-administration was linked to marked CAR-T cell expansion and tumor reduction following prior CAR-T failure. These findings suggest DNase I can be a transformative adjunctive therapy for CAR-T treatment by degrading extracellular DNA and NETs that lead to CAR-T cell exhaustion.
2026-05-29 19:39:20
Michael Liu and MJL Manager LLC have reported their stakes in Xenetic Biosciences (NASDAQ: XBIO) through a Schedule 13G filing. MJL Manager LLC holds 93,565 shares, representing 4.1% of the class, while Michael Liu individually holds 126,741 shares, accounting for 5.5%. Michael Liu is also identified as the sole control person of MJL Manager LLC, with both disclaiming beneficial ownership of each other's shares except for their pecuniary interest.
2026-05-16 00:39:34
This page provides a detailed stock quote and news updates for Xenetic Biosciences, Inc. (Nasdaq: XBIO), showing its current price, trading volume, and performance metrics. It also features recent news releases about the company's financial results, clinical advancements, and collaboration updates, alongside frequently asked questions regarding its public trading status.
2026-05-14 20:39:16
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed an amended Schedule 13G/A, disclosing beneficial ownership of 137,440 shares of Xenetic Biosciences (XBIO) Common Stock, representing 6.00% of the class. The filing indicates that certain funds managed by Renaissance Technologies LLC hold rights to dividends and sale proceeds from these shares. This disclosure updates a previous beneficial ownership statement, affirming Renaissance's passive investment in Xenetic Biosciences.
